Company intelligence / Profile preview

Illumen Therapeutics

Boulder, Colorado, United Statesillumentx.com ↗

Ownership: Private
Development stage: Other

Overview

Illumen Therapeutics is developing small molecule PARN inhibitors designed to increase functional p53 activity for cancer therapy. The approach aims to restore or enhance tumor-suppressing functions of p53 by targeting its regulation via PARN. Clinical results are not yet publicly reported; the company appears to be in preclinical or early development stages[1][3][6].

Therapeutic areas: Oncology
Modalities: Small molecules (PARN inhibitor drugs)
Industry: Biotech

Drug pipeline

1 asset

Illumen PARN inhibitor

Preclinical

Partnerships

University of Colorado Boulder/Venture Partners at CU Boulder[6]

Beyond the preview

Go deeper on Illumen Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Illumen Therapeutics.